Deep vein thrombosis (DVT) is a significant cause of morbidity and mortality with major physical and socioeconomic sequelae for patients. 1 Studies have shown that iliofemoral thrombosis is associated with a higher incidence of recurrent DVT and post-thrombotic syndrome. [2] [3] [4] Venous claudication is almost exclusively present in patients with iliofemoral DVT. 2, 5 So far, conventional treatment has been limited to anticoagulation and compression therapy alone. However, emerging data suggests that catheterdirected thrombolysis (CDT), in combination with appropriate anticoagulation, improves outcome with regard to recurrent DVT, venous obstruction, valve competence, and quality of life. [6] [7] [8] [9] Venous thrombectomy and pharmacomechanical thrombolysis (PhMT) have also been used for treating acute proximal thrombosis. [10] [11] [12] Although recent studies have shown favorable outcomes with CDT in the treatment of acute DVT, no large randomized studies are currently available to provide the needed evidence to support this treatment approach. Furthermore, the percentage of patients with DVT that would be candidates for thrombolysis, based on currently acceptable indications, has not been determined. This study was designed to determine the incidence of DVT and the number of patients who would be eligible for thrombolysis using standard criteria.
PATIENTS AND METHODS
This was a Health Insurance Portability and Accountability Act (HIPAA) compliant study that was approved by our institutional review board. The patient's informed consent was waved. Consecutive patients between November 2007 and April 2008 that were referred to our university hospital vascular lab to be evaluated for lower extremity venous thrombosis were prospectively collected. Indications for assessing these patients were signs and symptoms of venous thromboembolism and high-risk asymptomatic patients, such as those that underwent total joint arthropathy or complex neurosurgery procedures. Patients needing evaluation of their upper extremity veins were not included in the analysis. All patients were examined with duplex ultrasound (DU) scan using a technique previously described by our group. 13 A form accompanying each exam was completed to include demographic information, relevant clinical data, and DU scan findings including the extent, age, and distribution of the thrombus. Contraindications to thrombolysis were determined after DU scan exam by a staff physician. All DU scans were performed in an Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL) accredited laboratory by registered vascular technologists that had performed over 2000 tests for DVT before the initiation of the study. All exams of the current study were interpreted by a single experienced observer (N.L.).
The DU scan was performed in the supine position to detect obstruction and in the standing position for reflux. Retrograde flow of Ͼ1.0 seconds in common femoral, femoral, popliteal veins, and Ͼ0.5 seconds in deep femoral, deep calf veins, and the superficial veins were used.
14 Distribution and extent of thrombosis was evaluated in the supine position. It was graded as acute, acute on chronic, or chronic. Acute thrombosis was diagnosed based on the following DU scan criteria: 13 lack of compressibility, visualization of intraluminal thrombus, vein dilatation, and filling defects on color. The echotexture of the thrombus was homogenous and the wall-thrombus interface was smooth. Evidence of chronic thrombosis was defined as echogenic material in the lumen, heterogeneous thrombus echotexture, intraluminal webs, wall thickening, and normal or reduced luminal diameter. Presence of channels within the thrombus and reflux, with or without enlarged collaterals, were also indicative of chronic thrombosis. Acute on chronic thrombosis (recurrent thrombosis) was identified when a thrombus was found in a new vein segment that was not affected on previous thrombotic event. Thrombosis in a previously affected venous segment was detected by the presence of both echogenic and echolucent material that had a heterogeneous echotexture with dilatation of the vein and lack of compressibility. 13 Proximal DVT was defined as complete or partial thrombosis of the popliteal, femoral, deep femoral, common femoral, iliac veins, and inferior vena cava. Based on the plan of treatment with thrombolysis, proximal DVT was further subclassified as follows: femoropopliteal DVT which included the popliteal, femoral, and/or deep femoral vein. Iliofemoral DVT was defined as thrombosis of any part of the iliac and/or the common femoral vein, with or without associated femoropopliteal DVT. Calf DVT was defined as thrombosis in any of the following veins: anterior and posterior tibial, peroneal, gastrocnemial, and soleal veins. Anatomic location of the thrombus was categorized using the venous segmental disease score. 15 Patients with DVT were subsequently evaluated for potential thrombolysis. Standardized criteria for indications (Table I ) and contraindications (Table II) were used to evaluate each patient. 16 These data were entered prospectively into a customized Microsoft Access Database.
Statistical analysis. Data were analyzed using the SPSS (v 16, Chicago, Ill). Descriptive statistics were used for the patients' demographics. Differences in proportions were compared with the 2 test. When the expected value was 5 or less in any of the cells, the Fisher exact test was used.
RESULTS
Of the 576 evaluated patients, 281 (49%) were male and 295 (51%) were female with a mean age of 58 years, ranging from 10 to 99. DVT was detected in 112 patients (19.4%), 60 were male and 52 were female with a mean age of 62.5 years (range, 17-99). Segmental distribution, location, and age of thrombus are presented in Tables III and  IV . Proximal DVT was found in 81 patients (72%, 81/ 112), while isolated calf DVT was found in 31 patients (28%, 31/112). The anatomic distribution of proximal DVT included the femoral-popliteal segments in 61 patients (54%, 61/112) and extension at least to the iliofemoral segments in 20 patients (18%, 20/112). Of patients with proximal disease, acute thrombosis was found in 46 In patients with femoral-popliteal DVT, 32 (52%, 32/ 61) were acute, 13 were acute on chronic, and 11 were chronic. Of acute DVT patients, 19 involved multiple segments, whereas 13 were isolated to a single segment. In patients with iliofemoral DVT, 14 patients (70%, 14/20) were acute, and 6 (30%, 6/20) were chronic. Three patients had thrombus extending into the inferior vena cava (Table III) . In patients with isolated calf DVT, 26 patients (84%, 26/31) were acute (Table IV) . Of patients with proximal DVT, 26 had contraindications to thrombolysis (5 patients had absolute, and the remaining had relative contraindications). When evaluating the 14 patients with acute iliofemoral DVT, 10 patients were excluded based on standard contraindications (Table V) , leaving 4 eligible candidates for thrombolysis (Fig) . In patients with acute femoral-popliteal DVT, 24 were excluded from treatment. Eight patients had isolated popliteal vein thrombosis and 16 were excluded based on standard contraindications (Table V). This left 8 remaining eligible candidates for thrombolysis (Fig) .
In total, 12 patients were selected as potential candidates for treatment. This equates to a prevalence of 2% 
DISCUSSION
DVT of the lower extremity is a common disease that can result in death from pulmonary embolism or significant morbidity from chronic venous insufficiency. The reported incidence of DVT in the lower extremity is estimated at 1.0 to 1.6 events per 1000 per year. 17 Approximately 50% of patients presenting with symptomatic DVT in the lower extremity will have involvement of the proximal veins, 18 and about 30% will develop long-term complications and sequelae of the post-thrombotic syndrome. 19 Until recently, conventional treatment has been limited to the use of anticoagulation therapy and compression stockings alone with disregard to the subset of patients at a higher risk to develop long-term complications. New evidence, however, suggests that treatment strategies aimed at early thrombus removal may improve clinical outcomes by eliminating venous obstruction, preserving valve competence, and decreasing thrombus recurrence rates. [6] [7] [8] [9] The National Venous Registry 20 demonstrated favorable outcomes in treatment of acute iliofemoral DVT with catheter-directed thrombolysis. These outcomes were maintained at 1-year follow-up. After the Registry data, there have been several reports showing that local delivery of thrombolytics combined with mechanical thrombolysis provides good technical results with lower use of thrombolytics and lower complication rates. [20] [21] [22] [23] Two randomized trials 6, 7 subsequently looked at venous patency and reflux after thrombolysis and demonstrated that successful thrombolysis results in improved venous function. If thrombolysis improves venous function with lower incidence of reflux and obstruction, the expectation would be improved clinical outcome and better quality of life. Comerota et al 9 reported that patients who underwent thrombolysis had better overall physical functioning, less stigma, less health distress, and fewer post-thrombotic symptoms when compared with those treated with anticoagulation. Quality-oflife results were directly related to the initial success of thrombolysis.
To date, there is no large randomized prospective study available to support the use of these techniques. Recently, the 8th American College of Chest Physicians (ACCP) guidelines 24 included a level 2C recommendation, the use of CDT in combination with PhMT in extensive acute proximal DVT to reduce symptoms and post-thrombotic morbidity. Venous thrombectomy has also been used for treating acute proximal thrombosis with good long-term outcomes which were better when compared to anticoagulation alone. 10, 11 The National Institutes of Health (NIH) has recently funded the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) study, a multicenter randomized trial which will determine if PhMT can prevent postthrombotic syndrome. Another ongoing study in Norway, the Catheter-directed Venous Thrombolysis (CaVenT) trial, 25 has already randomized 86 patients. It is planned to enroll 200 patients to investigate the role of adjunctive CDT by evaluating its clinical efficacy and safety compared to conventional treatment alone. The number of patients with DVT that would benefit from thrombolysis is not known. Our study was designed to determine the number of potential candidates for treatment using specific guidelines. It is important to mention that these guidelines were taken from a consensus statement and are not strictly evidenced-based. In addition, we evaluated the reasons for which patients were not candidates and determined the prevalence of the different contraindications.
The overall incidence of thrombosis in our study was 19.4% (112/576). However, 26 patients had chronic thrombosis alone, and therefore the incidence of acute DVT was 14.8% (85/576). The reported incidence of patients examined in the vascular laboratory for acute DVT is 12% to 25%. 26 Candidates for thrombolysis will vary depending on the indications and contraindications that are used. Limiting thrombolysis to the iliofemoral veins, 4 of the 72 patients (5.6%) with acute thrombosis were candidates using standard contraindications (Table II) . However, of patients with acute iliofemoral DVT (n ϭ 14) almost 1 in 3 would be a candidate (28.6%).
Of patients with proximal venous thrombosis, there is little dispute in offering treatment for symptomatic acute iliofemoral DVT. Controversy, however, exists on the benefits of thrombolysis in femoropopliteal venous thrombosis. With reported lower risks of bleeding complications, PhMT has been offered in treating select patients. In the current study, 40% of patients with proximal DVT (32/81) were found to have acute thrombus localized to the femoropopliteal segments. From these patients, 8 had isolated popliteal vein thrombosis and 16 had contraindications to treatment, leaving 8 eligible for thrombolysis. Providing treatment to acute femoropopliteal DVT tripled our candidate population from 5.6% (4/72) in the iliofemoral veins to 16.7% (12/72) (Fig) .
A contraindication to thrombolytic therapy was present in 10 of 14 patients (71.4%) with iliofemoral DVT and in 24 of 32 patients (75%) with femoropopliteal DVT. Of the later, 13 patients had acute on chronic thrombosis and potentially could also have been candidates for treatment. However, patients with acute on chronic disease are usually treated for iliofemoral thrombosis. Overall, of patients with acute proximal DVT, 26.1% (12/46) were candidates for treatment. This is a significantly higher incidence when compared to the limited data in the literature. Casella et al 27 evaluated 260 patients with acute iliofemoral DVT and selected 18 for thrombolysis (6.9%; P ϭ .018 compared to our incidence of 28.6% in the iliofemoral veins). Their data were collected in a period of 5 years which means that less than 4 patients per year were candidates for thrombolysis. Markel et al 28 retrospectively reviewed patients seen in the vascular laboratory to rule out DVT. Of 833 patients referred, there were 209 with a diagnosis of DVT (25%). Using a nonstandardized list of contraindications, they found that 7% of patients with DVT (15/209) would be candidates for thrombolysis. This is similar to our findings where 12 of 112 patients were candidates (10.7%; P ϭ .29). However, this comparison cannot be accurate as they excluded only the calf veins and would treat patients with isolated popliteal DVT. If the 5 patients with DVT in the distal thigh and below were excluded, then their incidence was 4.8% (P ϭ .044).
The results of our study indicate that of patients evaluated for DVT, only 0.7% (4/576) would be eligible for thrombolysis considering the iliofemoral veins alone and 2.1% (12/576) when the femoropopliteal veins are included. The corresponding numbers for those with acute proximal DVT were 8.7% (4/46) and 26.1% (12/46). If one were to plan a trial with 200 patients with iliofemoral DVT, 28,800 would need to be evaluated. This number would be 9600 when the femoropopliteal veins are included. If the selection is done among patients with prox-imal acute DVT only, the corresponding numbers are 1900 and 633, respectively. These data were estimated from an overall acute DVT incidence of 15%. If we were to use a higher incidence, as reported in some series, the number of patients required would be correspondingly smaller. In contrast to other reports, our data distinguishes acute DVT from acute on chronic and chronic DVT giving a clearer account of the sample size needed. These figures should be considered when evaluating the number of centers required to recruit the necessary patient population for the trial.
CONCLUSIONS
This prospective study demonstrates that the number of patients who are candidates for thrombolysis is low. These data should be considered when recruiting centers to participate in ongoing trials. Further improvement in mechanical devices to allow treatment with low bleeding complications, and prospective studies with long-term data for proximal DVT, could increase the patient population eligible for thrombolysis. 
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